Maypro has entered into an exclusive distribution partnership with ClostraBio to introduce CLB101, a probiotic associated with gut barrier integrity and immune support benefits, to the North American market. The launch took place at SupplySide Global.

CLB101 is the first and only Anaerostipes caccae probiotic available for the dietary supplement market. This species is one of a few capable of directly producing butyrate, a short-chain fatty acid critical for gut barrier integrity and microbiome balance.

The strain metabolizes prebiotic fibers and other bacterial byproducts to support butyrate production, reinforcing the gut lining and promoting tight junction formation, and preventing the penetration of inflammatory molecules that can compromise gut integrity. It also calms gut inflammation by stimulating regulatory T-cell activity.

“A healthy gut begins with a healthy gut barrier,” said Abhijit Natu, vice president of sales and marketing at Maypro. “By supporting beneficial bacteria, strengthening the intestinal lining, and addressing factors that contribute to gut inflammation, CLB101™ represents a keystone probiotic strain for next-generation gut health formulations.”

“At ClostraBio, our mission is to leverage a science-driven, multi-pronged approach to address conditions of the lower gut, using novel next-generation probiotics,” said Ritu Shah, CEO of ClostraBio. “CLB101™ is the first probiotic designed to mimic the body’s natural butyrate cycle, offering a new frontier in gut integrity and immune support.”

CLB101 is delivered in a once-daily capsule and supports microbiome diversity, gut barrier function, digestive comfort, and regularity.